IMPORTANCE Studies focused on recurrent longitudinally extensive transverse myelitis (rLETM) are lacking.
nally extensive" designation indicates that sagittal spinal magnetic resonance images have an abnormal T2-weighted signal extending across at least 3 vertebral segments. 2, 4, 5 The outcomes of LETM include poor recovery, severe disability, and mortality, especially when diagnosis and immunotherapy are delayed. 2, 5 In single-attack LETM, AQP4-IgG seropositivity predicts recurrence or conversion to NMO. 4 Reported AQP4-IgG seropositivity rates are underestimated owing to assay insensitivity and immunotherapy effects. 1 A blinded international collaborative comparison of the sensitivities of currently used assay methods (indirect immunofluorescence [IIF] , cell-based assay [CBA] , enzymelinked immunosorbent assay [ELISA] , immunoprecipitation, and fluorescence-activated cell sorting [FACS] ) confirmed that assays using recombinant antigen are more sensitive than IIF assays. 1 The AQP4-IgG detection rate in recurrent LETM (rLETM) has not been studied systematically with recombinant antigen-based assays, nor have clinical and demographic characteristics associated with rLETM been clearly defined. In this article, we report an updated estimate of the AQP4-IgG positivity rate for Mayo Clinic patients with rLETM, 25% of whom were categorized as NMO-IgG negative with firstgeneration IIF testing. We retested stored serum specimens using 3 recombinant antigen-based assays.
Methods
The study protocol was reviewed and approved by the Mayo Clinic Institutional Review Board (IRB 08-006647). Only patients providing written informed consent for research studies were included.
Detection of NMO/AQP4-IgG
Serum samples were collected at clinic visits, particularly at acute exacerbations. All testing was performed under blinded conditions. The IIF substrate was a composite cryosection of normal adult mouse brain, kidney, and gut tissues. 7 Patients whose serum samples tested positive at IIF were not retested with other assays owing to the 99% specificity of IIF for NMO. All serial samples yielding a negative IIF result were retested sequentially with assays using recombinant human AQP4. The M1 isoform of AQP4 was the antigen in commercial ELISA kits (RSR [Kronus, Ltd]; results ≥5 U/mL were categorized as positive) and in the transfected immunofluorescence CBA (Euroimmun; each sample was categorized as positive or negative by 3 experienced readers).
1
The in-house FACS assay used both M23 and M1 isoforms of AQP4 (unless serum volume was insufficient to analyze in independent assays). For the FACS assay, human embryonic kidney cells (HEK 293) were transfected transiently with a plasmid (pIRES2-AcGFP) encoding both green fluorescent protein (GFP) and either AQP4-M1 or AQP4-M23. After 36 hours, FcR Blocking Reagent (Miltenyi Biotech catalog No. 130-059-901) was added to the mixed population of cells (transfected expressing AQP4 on the surface and GFP in the cytoplasm and nontransfected lacking AQP4 and GFP). Patient serum (heatinactivated at 56°C for 30 minutes) was added to 100 000 cells at a 20% concentration in a final volume of 100 μL. After incubation (at 4°C for 30 minutes) and washing, the cells were resuspended with 100 μL of AlexaFluor 647-conjugated goat anti-human IgG (Invitrogen catalog No. A21445, 1:500 dilution), held on ice for 30 minutes, washed, fixed with 4% paraformaldehyde, and examined with flow cytometry (BD FACS LSRII; Becton, Dickinson and Co).
Results were obtained with acquisition/analysis software. Binding of a patient's IgG to the AQP4-transfected (GFP-positive) cells was measured in terms of the intensity of AlexaFluor 647 fluorescence. The median fluorescence intensity (MFI) value for AlexaFluor 647 corresponding to IgG bound to AQP4-transfected cells was expressed as a ratio of the MFI value for that patient's IgG binding to nontransfected control cells in the same aliquot (MFI AQP4-transfected cells/MFI nontransfected cells = AQP4-IgG binding index). The AQP4-IgG binding index values were considered positive if they were 3 or higher for assays using AQP4-M23-transfected cells or 2 or higher for those using AQP4-M1-transfected cells. All patients were clinically evaluated at Mayo Clinic locations in Rochester, Minnesota; Scottsdale, Arizona; or Jacksonville, Florida. We compared clinical characteristics of the rLETM group, the 140 AQP4-IgG-positive patients with NMO, and a subgroup of 20 patients with NMO whose course started with 2 or more attacks of transverse myelitis (rLETM-onset NMO). The following clinical data were collected: date of birth, sex, ethnicity, age at disease onset, coexisting autoimmune disorders, disease duration, onset symptom, attack severity (with severe defined as unable to walk at nadir for spinal or brain attack), attack type and frequency, and visual acuity. We recorded times to permanent motor disability (Expanded Disability Status Scale score ≥6 [intermittent or unilateral assistance required to walk 100 m with or without resting] or ≥8 [restricted to bed or chair or perambulated in wheelchair for ≥6 months]). Data were collected retrospectively through review of case records. t (or Wilcoxon rank sum) tests for continuous data. Disease characteristics over the course of all attacks per patient were compared using regression models with generalized estimating equations, using logistic regression for binary and linear regression for continuous data. Therapy "intervals" were defined for each patient to correspond to periods during which long-term immunosuppressant therapy was (or was not) being used. Relapse rates were compared between on-therapy and off-therapy intervals using linear regression models with generalized estimating equations. Disability outcomes were compared between groups using log-rank tests, and the risk of these outcomes was estimated using the Kaplan-Meier method. Adjusted associations of patient characteristics with these outcomes were assessed with Cox proportional hazards regression models. All statistical testing was considered as exploratory data analysis. Thus, no adjustments were made for multiple testing. Data were analyzed using SAS statistical software (version 9; SAS Institute Inc), and figures were created using R software (http://www.R-project.org/). Differences were considered statistically significant at P < .05.
Patients and Samples

Results
"Seronegative" Patients With rLETM Reclassifiable as AQP4-IgG Positive
Indirect immunofluorescence assay testing of serial specimens from 48 patients with rLETM yielded a cumulative seropositivity rate of 75% ( Figure 1 ). Stored specimens were available to retest 11 of the 12 patients classified as seronegative. Six specimens yielded a positive result with at least 1 recombinant antigen-based assay. This increased the cohort's AQP4-IgG-positive rate to 89% (42 of 47 patients): 89% (42 of 47 patients) for FACS, 85% (40 of 47) for CBA, and 81% (38 of 47) for ELISA ( Table 1) . Testing a patient serially in the disease course enhanced AQP4-IgG detection (eg, Figure 2A ). Of the 5 patients who were persistently AQP4-IgG negative, 3 had only 1 available specimen for retesting, and 4 were receiving immunotherapy when the specimen was obtained.
Serostatus Conversion From Positive to Negative With Immunotherapy
Of the 6 patients reclassified as AQP4-IgG positive after retesting with recombinant antigen-based assays, 1 converted to seronegative after rituximab treatment ( Figure 2B ).
Demographic Differences Between AQP4-IgG-Negative and AQP4-IgG-Positive Patients With rLETM
Among the 5 AQP4-IgG-negative patients, men outnumbered women (3:2 ratio), but women outnumbered men (5:1 ratio) among the 42 AQP4-IgG-positive patients with rLETM. The AQP4-IgG-negative patients were on average younger at disease onset than the AQP4-IgG-positive patients. No other demographic or clinical differences were observed between AQP4-IgG-positive and AQP4-IgG-negative patients with rLETM ( Table 2) .
Demographic and Phenotypic Similarities Between AQP4-IgG-Positive Patients With rLETM or rLETM-Onset NMO
Patients positive for AQP4-IgG with rLETM or rLETM-onset NMO did not differ significantly with respect to sex ratio, ethnicity, age at disease onset, frequency of coexisting autoimmune diseases, annualized relapse rate, severity at onset, or subsequent attacks (Table 2) , and Kaplan-Meier analysis revealed no significant differences in time to motor disability ( Figure 3 and Table 2 ). In AQP4-IgG-positive patients at 5 years from disease onset, 36% with rLETM and 41% with rLETMonset NMO would be expected to require a cane to walk (Figure 3 ). In contrast, at 5 years after disease onset, the outcome for the whole AQP4-IgG-positive NMO group appeared more favorable with respect to motor disability, with 22% expected to require a cane to walk ( Figure 3 and Table 2 ). Small numbers precluded comparison with the 5 patients with AQP4-IgG-negative rLETM, although all 5 in this group remained ambulatory at a median follow-up interval of 30 months after onset. Kaplan-Meier analysis revealed no significant differences Patients who were AQP4-IgG positive had a shorter median disease duration (first attack to last follow-up) than those with rLETM-onset NMO (59 vs 133 months; P = .001). The median interval from disease onset to first attack of ON in patients with rLETM-onset NMO (54 months) was similar to the median disease duration in AQP4-IgG-positive patients with rLETM (59 months). Furthermore, the median attack number for the patients with rLETM was 3 (range, 2-22). For the patients with rLETM-onset NMO, the first ON occurred after a median of 3 transverse myelitis attacks (range, 2-19).
Relapse Rate in rLETM After Immunosuppressant Therapy
A total of 192 attacks were recorded for the 47 patients with rLETM whose serostatus was known. Immunosuppressant therapy (azathioprine, mycophenolate mofetil, oral prednisone, monthly intravenous methylprednisolone, rituximab, eculizamab, or combinations) was administered for half the cu- c These 16 patients may have more than 1 autoimmune condition, including autoimmune thyroid disease (n = 10), antiphospholipid syndrome (n = 1), Sjögren syndrome (n = 2), rheumatoid arthritis (n = 3), thrombotic thrombocytopenic purpura (n = 1), and type 1 diabetes mellitus (n = 1). d Posterior medullary lesion in 1 patient; 1 patient ultimately developed progressive multifocal leukoencephalopathy after prolonged immunosuppression.
e Where not otherwise indicated, values for CSF findings indicate numbers of patients. f An EDSS score of 6 indicates that the patient requires intermittent or unilateral assistance (canes, crutches, or braces) to walk 100 m, with or without resting. An EDSS score of 8 indicates that the patient is restricted to bed or chair or perambulated in a wheelchair but may be out of bed much of the day, retains many self-care functions, and generally has effective use of his or her arms. g Long-term immunosuppressant therapy included azathioprine, mycophenolate mofetil, oral prednisone, monthly intravenous methylprednisolone, rituximab, eculizamab, or combinations. h Comparison between annualized relapse rate with and without therapy in each subgroup.
mulative disease duration (mean, 61% and 52% of disease duration for AQP4-IgG-positive and AQP4-IgG-negative patients, respectively). Similar to results in patients with NMO, the mean (SD) annualized relapse rate for AQP4-IgG-positive patients with rLETM was 2.5 (2.5) when they were not receiving immunosuppressant therapy but 0.4 (0.5) when they were (P < .001); the comparable rates for seronegative patients were 1.4 (1.4) vs 0.3 (0.3) (P < .001). Interpretation is limited by small numbers ( Table 2) .
Discussion
This study, the first to our knowledge to focus on patients with relapsing LETM, had several important observations. First, recombinant antigen-based assays significantly increase the AQP4-IgG detection rate in patients with rLETM; AQP4-IgGnegative adults with rLETM are rare. Second, AQP4-IgGpositive patients with rLETM are phenotypically similar to AQP4-IgG-positive patients with NMO with rLETM onset. Third, immunosuppressant therapy reduces the relapse rate in both AQP4-IgG-positive and AQP4-IgG-negative patients with rLETM. The various assays currently used for clinical detection of AQP4-IgG differ in sensitivity. Using 3 different recombinant antigen-based assays, we detected AQP4-IgG in half of the patients with NMO initially deemed seronegative by IIF, reducing the seronegativity rate from 25% to 11%. Assays using recombinant antigen also enabled AQP4-IgG detection in the retesting of archival serum specimens collected serially and initially reported as negative (service IIF evaluation). Three of the 5 patients with rLETM who remained classified as seronegative had only a single specimen, and 4 were receiving immunotherapy when the sample was obtained. Thus, the timing of blood sample collection and the use of immunosuppressant therapy may influence AQP4-IgG detection.
When optimized assays were used for AQP4-IgG detection, the seronegative rate in this adult rLETM cohort of 43 patients was only 7%, much lower than that reported elsewhere. 1, 7, 9 As is true for patients with NMO, the sexes were similarly represented in AQP4-IgG-negative patients with rLETM, with a 5:1 female to male ratio in AQP4-IgG-positive patients. 10, 11 For patients with disease onset before age 18 years, 2 of 4 were AQP4-IgG positive and female (age at onset, 15 and 17 years), and 2 were AQP4-IgG negative and male (age at onset, 3 and 6 years). In contrast to adults with multiple sclerosis, 14% of children with multiple sclerosis have longitudinally extensive spinal cord lesions. 12 Therefore, the 2 seronegative boys in this report may have had multiple sclerosis, with initial attacks being rLETM. Our study suggests that a proportion of seropositive patients with rLETM may develop ON with time and thus fulfill Wingerchuk et al 3 NMO criteria because (1) patients with rLETM are similar to those with rLETM-onset NMO with respect to sex ratio, age at onset, and frequency of coexisting autoimmune diseases and clinical characteristics (relapse rate, attack severity, and disability outcome); (2) they had a shorter duration of follow-up than NMO and rLETM-onset NMO groups; and (3) their duration of follow-up is similar to the median time from onset to first ON for patients with NMO with initial rLETM onset. Furthermore, the first ON attack in patients with rLETMonset NMO occurred after a median of 3 LETM attacks, and the median number of LETM attacks in the rLETM group was 3. As is true for AQP4-IgG-positive patients with NMO, immunosuppressant therapies significantly reduce the relapse rate in AQP4-IgG-positive patients with rLETM. Because these patients, like those with rLETM-onset NMO, have a worse motor outcome than the entire AQP4-IgG-positive NMO cohort, early initiation of attack prevention therapies is even more critical in this group.
This study and other recent reports from the United States and Europe indicate that assays detecting IgG binding to cells expressing recombinant AQP4 with quantitative flow cytometry (FACS) or visual observation (CBA) are more sensitive than ELISA and significantly more sensitive than immunoprecipitation and tissue-based immunofluorescence assays in aiding the diagnosis of NMO and NMO spectrum disorders. 1, 11, [13] [14] [15] [16] [17] For patients considered at high risk for AQP4 autoimmunity (including those with rLETM), testing for AQP4-IgG by more sensitive CBA or FACS assays is recommended if less sensitive assays yield negative results. Retesting a later sample is warranted if initial test results are negative in a high-risk patient. Major disability outcomes were similar in AQP4-IgG-positive patients with rLETM and those with rLETM-onset NMO. At 5 years after onset, 36% of patients with rLETM and 41% with rLETM-onset NMO were expected to need a cane (Expanded Disability Status Scale [EDSS] score, 6; intermittent or unilateral assistance [canes, crutches, or braces] required to walk 100 m with or without resting) (P = .94); a lower frequency (22%) was expected for the total AQP4-IgG-positive NMO group. The rLETM-onset NMO group included AQP4-IgG-positive patients with NMO who initially presented with 2 attacks of transverse myelitis.
